Mesoblast (NASDAQ:MESO) Reaches New 52-Week High – Time to Buy?

Mesoblast Limited (NASDAQ:MESO) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $20.97 and last traded at $20.75, with a volume of 322856 shares trading hands. The stock had previously closed at $17.53.

Wall Street Analyst Weigh In

MESO has been the topic of a number of recent analyst reports. Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Piper Sandler raised their target price on shares of Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. Finally, Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Mesoblast has an average rating of “Hold” and a consensus price target of $13.50.

Mesoblast Trading Up 23.3 %

The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $11.24 and a 200 day simple moving average of $8.66.

Institutional Investors Weigh In On Mesoblast

A number of large investors have recently added to or reduced their stakes in MESO. Perkins Coie Trust Co raised its holdings in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after acquiring an additional 1,500 shares in the last quarter. Signaturefd LLC lifted its position in Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the period. Lazari Capital Management Inc. grew its stake in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after buying an additional 3,300 shares in the last quarter. Rathbones Group PLC bought a new position in Mesoblast in the 2nd quarter valued at about $95,000. Finally, XTX Topco Ltd acquired a new position in shares of Mesoblast in the 2nd quarter valued at approximately $103,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.